Eur Rev Med Pharmacol Sci 2019; 23 (24): 10918-10930
DOI: 10.26355/eurrev_201912_19795

CircRNA_0016418 expedites the progression of human skin melanoma via miR-625/YY1 axis

Y. Zou, S.-S. Wang, J. Wang, H.-L. Su, J.-H. Xu

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China. jinhuaxu@fudan.edu.cn


OBJECTIVE: Some circular RNAs (circRNAs) have been testified to play crucial roles in the regulation of skin melanoma, including circRNA_0016418 (circ0016418). However, the regulatory mechanism of circ0016418 in skin melanoma is undiscovered.

MATERIALS AND METHODS: The RNA expression was examined through quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and associated-proteins levels were measured via Western blot. Cell counting kit-8 (CCK-8) assay was used for detecting cell proliferation. Transwell assay was conducted to assess the abilities of migration and invasion. The target relation was analyzed by Dual-Luciferase reporter assay.

RESULTS: The levels of circ0016418 and Yin Yang 1 (YY1) were up-regulated in skin melanoma tissues and cells. Knockdown of both circ0016418 and YY1 had suppressive effects on proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of skin melanoma cells. YY1 overexpression reverted the inhibitory effects on skin melanoma cells caused by circ0016418 knockdown. Circ0016418 negatively modulated microRNA-625 (miR-625) expression and miR-625 directly targeted YY1. Circ0016418 functioned as a competitive endogenous RNA (ceRNA) of miR-625 to regulate YY1 expression.

CONCLUSIONS: Circ0016418 regulated proliferation, migration, invasion, and EMT of skin melanoma cells through miR-625/YY1 axis. Circ0016418 might be a useful indicator of the therapeutic strategies of skin melanoma.

Free PDF Download

To cite this article

Y. Zou, S.-S. Wang, J. Wang, H.-L. Su, J.-H. Xu
CircRNA_0016418 expedites the progression of human skin melanoma via miR-625/YY1 axis

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 24
Pages: 10918-10930
DOI: 10.26355/eurrev_201912_19795